Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Kiniksa Pharmaceuticals, Ltd. (KNSA)
|
Add to portfolio |
|
|
|
| Price: |
$11.70
| | Metrics |
| OS: |
139.5
|
M
| |
|
|
| Market cap: |
$1.63
|
B
| |
|
|
|
Net cash:
|
$191
|
M
| |
$1.37
|
per share
|
|
EV:
|
$1.44
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 220.2 | 38.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 471.2% | | | | | | |
| Cost of goods sold | 47.0 | 9.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 173.2 | 28.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 78.7% | 74.2% | | | | | |
| Selling, general and administrative | 98.0 | 85.9 | 45.3 | 35.0 | | | |
| Research and development | 65.5 | 99.3 | 112.0 | 135.0 | 86.6 | 56.4 | 17.4 |
| General and administrative | | | | | 21.6 | 9.0 | 6.6 |
| EBIT | 9.8 | -156.6 | -157.4 | -170.0 | -108.2 | -65.4 | -24.0 |
| EBIT margin | 4.4% | -406.4% | | | | | |
| Pre-tax income | 11.0 | -156.5 | -156.2 | -163.9 | -103.4 | -64.9 | -23.9 |
| Income taxes | -172.3 | 1.4 | 5.2 | -2.0 | -0.2 | 0.0 | 0.0 |
| Tax rate | | | | 1.2% | 0.2% | | |
| Net income | 183.4 | -157.9 | -161.4 | -161.9 | -103.2 | -64.9 | -24.0 |
| Net margin | 83.3% | -409.7% | | | | | |
| |
| Diluted EPS | $2.60 | ($2.30) | ($2.61) | ($2.99) | ($3.49) | ($35.85) | ($91.61) |
| Shares outstanding (diluted) | 70.4 | 68.6 | 61.8 | 54.0 | 29.5 | 1.8 | 0.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|